4 April
2024
ECO Animal Health Group
plc
("ECO" or
the "Company")
Disposal of non-core product line
Disposal streamlines ECO Animal Health's
product and pipeline focus
ECO
Animal Health Group plc (AIM: EAH), a rapidly growing global
animal health company with a portfolio of marketed veterinary
products and a maturing proprietary R&D pipeline, today
announces the disposal of ECOmectin® Horsepaste to ACME Drugs S.r.l
in Italy ("ACME"), its long-term manufacturing partner, for a total
consideration of €1.3m.
Continuing to
streamline the business
ECO is focused on treatment and prevention of disease
in pigs and poultry. ECOmectin® Horsepaste is a branded treatment
for equine parasites based upon the ivermectin active ingredient
and has for some time been non-core to the business.
The
Transaction
ACME has acquired all the marketing authorisations
held by ECO for the ECOmectin® Horsepaste, together with the
intellectual property, manufacturing and distribution arrangements
and existing inventory ("the Transaction"). The marketing
authorisations are principally within the UK and EU. In
addition, ACME has been granted a trademark licence to market and
sell the horse paste under the ECOmectin® brand.
The total consideration for the Transaction is €1.3m;
€500,000 was paid on signature of the sale and purchase agreement
with an undertaking to pay two further payments of €400,000 each on
the date which is 18 months after completion and 36 months after
completion. These two elements of deferred consideration are
unconditional and supported with a bank guarantee which will be put
in place within 45 days.
The revenue derived from this business in the year
ending 31 March 2024 was £814,000 (2023 £988,000).
Reinvesting to
support our pipeline
The Board believes that the Transaction further
streamlines ECOs focus on its core species of pigs and poultry and
in particular on developing its highly innovative pipeline of
vaccines and preventatives. It is intended that the funds received
from the Transaction will be invested in research and development
to support new product development.
David Hallas, Chief
Executive Officer of ECO Animal Health Group plc, commented:
"The disposal of
ECOmectin®
Horsepaste is in line with our
stated intention of focusing on treatments and preventatives in
pigs and poultry and this enables us to increase investment in our
R&D pipeline. The brand and the broader business is a good fit
for ACME Drugs S.r.l and we are pleased that the business will be
taken forward by a committed
owner.
"We continue to
look for value accretive opportunities both within our portfolio
and outside and for opportunities to reinvest in our R&D
pipeline to support future growth."
-Ends-
For further
information please contact:
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
ICR Consilium
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices
including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a proprietary,
patented medication which is effective against both respiratory and
intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com